Max Nisen, Columnist

Biotech Fumbles the Start of Its Biggest Showcase

A flurry of bad news and small deals dents industry sentiment.

January 9, 2018 at 1:30 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

This article is for subscribers only.

Day one of the annual J.P. Morgan Healthcare Conference -- typically the biotech industry's biggest showcase of the year -- was something of a dud.

The Nasdaq Biotech Index (NBI) fell as much as 2 percent on Monday. That's not a rout, but it is a disappointment.